Lead poisoning in children.
Increased lead exposure and increased body burden of lead remains a significant problem for children in the United States. With the increased use of blood level screening methods, a large percentage of children in many industrialized countries are being tested as a being at risk. A controversy continues over the definition of what population to screen and at what age to screen. There are parts of the United States, especially rural areas and health maintenance organization populations, where screening for lead exposure has not been productive. A new drug, DMSA (meso 2,3-dimercaptosuccinic acid) has been approved for oral chelation of children with increased body burden of lead. At the present time it is labeled for use in children with blood lead concentrations in excess of 45 micrograms/dL. Evidence exists that DMSA is effective in lowering the blood lead concentrations in children with levels between 25 and 45 micrograms/dL. The long-term effectiveness of chelation at lower levels is at present uncertain. There remains no substitution for strict environmental decontamination in the home environment of children and the workplace environment of their parents.
Berlin
C M
CM
Department of Pediatrics, Milton S. Hershey Medical Center, Pannsylvania State University College of Medicine, Harshey 17033-0850, USA.
D002614:Chelating Agents / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007855:Lead Poisoning / Q000175:diagnosis* / Q000188:drug therapy; D004113:Succimer / Q000627:therapeutic use
D002614:Chelating Agents; D004113:Succimer